Sergio Giralt, MD

Articles

VOD: Ensuring Best Outcomes

February 26th 2024

Experts share tips for treating patients with VOD with defibrotide, including strategies to ensure best possible outcomes.

Treating VOD: Standard-of-Care Approach

February 19th 2024

Mitchell Cairo, MD, shares his standard-of-care approach to treating VOD and the role of defibrotide, the only FDA-approved drug for VOD.

A Multidisciplinary Approach to Managing VOD

February 19th 2024

Sergio Giralt, MD, leads a discussion on the importance of a multidisciplinary team approach in caring for patients with VOD, from recognizing early signs to treating and monitoring the disease.

Challenges in Diagnosing VOD

February 12th 2024

Mitchell Cairo, MD, and Sergio Giralt, MD, provide insights about the challenges in diagnosing VOD and the need to educate physicians about risk factors for VOD, its pathophysiology, and the importance of early detection.

Diagnosing VOD

February 12th 2024

A review of the diagnostic criteria for veno-occlusive disease for pediatric and adult patients.

VOD Risk Factors

February 12th 2024

Experts discuss the risk factors associated with VOD and which high-risk patients should be monitored for signs and symptoms of this disease.

VOD Overview

February 12th 2024

Mitchell Cairo, MD, and Sergio Giralt, MD, offer an overview of veno-occlusive disease, an endothelial damage syndrome, and its prognosis.

COMING SOON: Insights: Early Detection and Treatment of Veno-Occlusive Disease

December 19th 2023

Sergio Giralt, MD, provides a look at an upcoming OncLive Insights program in which he will offer insights on the evolving treatment landscape for patients with veno-occlusive disease.

Dr. Giralt on the Evaluation of Ide-cel in Triple-Class Exposed R/R Myeloma

February 27th 2023

Sergio A. Giralt, MD, discusses the investigation of idecabtagene vicleucel vs standard-of-care regimens in patients with triple-class exposed relapsed/refractory multiple myeloma in the phase 3 Karmma-3 trial.

Dr. Giralt on Long-Term Outcomes with HSCT in Multiple Myeloma

January 25th 2023

Sergio A. Giralt, MD, discusses long-term outcomes with hematopoietic stem cell transplant in multiple myeloma

Dr. Giralt on Future of Transplant in Multiple Myeloma

February 2nd 2017

Sergio Giralt, MD, a professor of Medicine at Memorial Sloan Kettering Cancer Center, discusses the future role of transplantation in patients with multiple myeloma as well as other hematologic malignancies.